Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.18)
# 3,645
Out of 5,182 analysts
18
Total ratings
31.25%
Success rate
-0.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $12.93 | +441.38% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $3.87 | +236.35% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $150 → $250 | $1.09 | +22,835.78% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $7.66 | +683.29% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $6.67 | +799.55% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $3.64 | +174.73% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.33 | +952.63% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.51 | +429.80% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $3,000 | $6.14 | +48,759.93% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $12.05 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.34 | +259.28% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $2.27 | +436,123,248.02% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $32.24 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $2.62 | +472.52% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $12.93
Upside: +441.38%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $3.87
Upside: +236.35%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150 → $250
Current: $1.09
Upside: +22,835.78%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $7.66
Upside: +683.29%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $6.67
Upside: +799.55%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $3.64
Upside: +174.73%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.33
Upside: +952.63%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.51
Upside: +429.80%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $3,000
Current: $6.14
Upside: +48,759.93%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.05
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $3.34
Upside: +259.28%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $2.27
Upside: +436,123,248.02%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $32.24
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $2.62
Upside: +472.52%